BerGenBio

BerGenBio ASA - Registration of reverse share split

Bergen, Norway, 3 June 2024. Reference is made to the stock exchange

announcement made by BerGenBio ASA (the "Company") on 23 May 2024 regarding the

Company's annual general meeting resolving a reverse share split of the

Company's shares in the ratio 100:1. The reverse share split has today been

registered with the Norwegian Register of Business Enterprises. Following such

registration, the share capital of the Company is NOK 390,871,160 divided into

39,087,116 shares, each with a nominal value of NOK 10.

For further information, please contact:

Martin Olin, CEO, BerGenBio ASA

Rune Skeie, CFO, BerGenBio ASA

About BerGenBio ASA

BerGenBio is a clinical-stage biopharmaceutical company focused on developing

transformative drugs targeting AXL as a potential cornerstone of therapy for

aggressive diseases, including cancer and severe respiratory infections. The

Company is focused on its proprietary lead candidate bemcentinib a potentially

first-in-class selective AXL inhibitor in development for STK11 mutated NSCLC

and severe respiratory infections. BerGenBio is based in Bergen, Norway with a

subsidiary in Oxford, UK. The Company is listed on the Oslo Stock Exchange

(ticker: BGBIO). For more information, visit www.bergenbio.com.

This information is published in accordance with the requirements of the

Continuing Obligations pursuant to Oslo Rule Book II.

AI Terminal